<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Int Med Res</journal-id><journal-id journal-id-type="iso-abbrev">J. Int. Med. Res</journal-id><journal-id journal-id-type="publisher-id">IMR</journal-id><journal-id journal-id-type="hwp">spimr</journal-id><journal-title-group><journal-title>The Journal of International Medical Research</journal-title></journal-title-group><issn pub-type="ppub">0300-0605</issn><issn pub-type="epub">1473-2300</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28661264</article-id><article-id pub-id-type="pmc">5805213</article-id><article-id pub-id-type="doi">10.1177/0300060517713405</article-id><article-id pub-id-type="publisher-id">10.1177_0300060517713405</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Report</subject></subj-group></article-categories><title-group><article-title>Efficacy of solifenacin in the prevention of short-term complications after laparoscopic radical prostatectomy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Ranxing</given-names></name><xref ref-type="aff" rid="aff1-0300060517713405">1</xref><xref ref-type="author-notes" rid="fn1-0300060517713405">*</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Lijie</given-names></name><xref ref-type="aff" rid="aff1-0300060517713405">1</xref><xref ref-type="author-notes" rid="fn1-0300060517713405">*</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Gaofeng</given-names></name><xref ref-type="aff" rid="aff1-0300060517713405">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yu</surname><given-names>Jianjun</given-names></name><xref ref-type="aff" rid="aff1-0300060517713405">1</xref><xref ref-type="aff" rid="aff2-0300060517713405">2</xref><xref ref-type="corresp" rid="corresp1-0300060517713405"/></contrib></contrib-group><aff id="aff1-0300060517713405"><label>1</label>Department of Urology, Shanghai Jiao Tong University Affiliated Sixth People&#x02019;s Hospital, Shanghai, China</aff><aff id="aff2-0300060517713405"><label>2</label>Department of Urology, Shanghai Jiao Tong University Affiliated Sixth People&#x02019;s Hospital South Campus, Shanghai, China</aff><author-notes><fn fn-type="equal" id="fn1-0300060517713405"><label>*</label><p>These authors contributed equally to this work.</p></fn><corresp id="corresp1-0300060517713405">Jianjun Yu, Shanghai Jiao Tong University Affiliated Sixth People&#x02019;s Hospital South Campus, 6600 Nanfeng Road, New Nanqiao Town, Fengxian District, Shanghai, 201499, China. Email: <email>ycx917@126.com</email></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2017</year></pub-date><volume>45</volume><issue>6</issue><fpage>2119</fpage><lpage>2127</lpage><history><date date-type="received"><day>7</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>12</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/3.0/">http://www.creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><sec><title>Objective</title><p>
To evaluate the efficacy of solifenacin in the prevention of short-term complications after laparoscopic radical prostatectomy (LRP).</p></sec><sec><title>Methods</title><p>This randomized placebo-controlled study enrolled patients with histologically proven prostate cancer who underwent LRP. The patients were randomized to receive either solifenacin (5&#x02009;mg once daily; study group) or placebo (control group) for the 15-day period beginning on the first day after surgery. The mean duration of detrusor overactivity (DO), the frequency of DO, the duration of macroscopic haematuria, and the days before catheter removal were recorded. The International Continence Society Short Form Male questionnaire, bladder neck stenosis episodes, and maximum urinary flow rate were evaluated at 1 month after surgery. The side-effects after using solifenacin were also recorded.</p></sec><sec><title>Results</title><p>A total of 120 patients were randomly assigned to the study group (<italic>n</italic>&#x02009;=&#x02009;62) or the control group (<italic>n</italic>&#x02009;=&#x02009;58). There were significantly lower rates of DO episodes during the daytime and night-time, haematuria and transient incontinence in the study group compared with the control group.</p></sec><sec><title>Conclusion</title><p>Solifenacin was a well-tolerated and effective treatment for the prevention of complications after LRP, with the main advantage compared with placebo being the decreased frequency of DO episodes during the daytime and night-time.</p></sec></abstract><kwd-group><kwd>Laparoscopic radical prostatectomy</kwd><kwd>complications</kwd><kwd>solifenacin</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-0300060517713405"><title>Introduction</title><p>Prostate cancer (PCa) is a significant contributor to morbidity and mortality in males.<sup><xref rid="bibr1-0300060517713405" ref-type="bibr">1</xref></sup> Although brachytherapy and radiotherapy have achieved much progress, laparoscopic radical prostatectomy (LRP) remains an appropriate method that is universally accepted, especially for localized PCa.<sup><xref rid="bibr2-0300060517713405" ref-type="bibr">2</xref></sup> LRP is a challenging operation that demands a high level of surgical expertise and experience. The complications after LRP include urethrovesical anastomotic urinary leakage, urinary incontinence, haematuria, and bladder neck stenosis.<sup><xref rid="bibr3-0300060517713405" ref-type="bibr">3</xref></sup> Detrusor overactivity (DO) is defined by the International Continence Society as the urodynamic observation of involuntary detrusor contractions during the filling phase that can be spontaneous or provoked.<sup><xref rid="bibr4-0300060517713405" ref-type="bibr">4</xref></sup> The symptoms of DO usually present a few days or months after LRP.<sup><xref rid="bibr5-0300060517713405" ref-type="bibr">5</xref></sup> DO can appear with other complications and the end result would be a delay in healing time.<sup><xref rid="bibr6-0300060517713405" ref-type="bibr">6</xref></sup></p><p>Antimuscarinics are considered the first-line pharmacotherapy for DO.<sup><xref rid="bibr7-0300060517713405" ref-type="bibr">7</xref></sup> Solifenacin, a once-daily competitive muscarinic receptor antagonist has been found to improve DO symptoms, including incontinence, urgency, and frequency, with a low incidence of treatment-limiting adverse events.<sup><xref rid="bibr8-0300060517713405" ref-type="bibr">8</xref></sup> Solifenacin has been used in several trials post-radical prostatectomy,<sup><xref rid="bibr9-0300060517713405" ref-type="bibr">9</xref><xref rid="bibr10-0300060517713405" ref-type="bibr"/>&#x02013;<xref rid="bibr11-0300060517713405" ref-type="bibr">11</xref></sup> but there is a lack of research for the application of solifenacin in cases of LRP. The main difference in this current study is that all of the patients had undergone laparoscopic procedures, rather than robotic or open procedures, for which there are few data. The objective of the present study was to evaluate the efficacy of solifenacin in the prevention of complications after LRP.</p></sec><sec sec-type="subjects" id="sec2-0300060517713405"><title>Patients and methods</title><sec id="sec3-0300060517713405"><title>Study participants</title><p>This randomized placebo-controlled study enrolled a consecutive series of patients with histologically proven PCa who underwent LRP between March 2011 and October 2016 in the Department of Urology, Shanghai Jiao Tong University Affiliated Sixth People&#x02019;s Hospital, Shanghai, China. The inclusion criteria included: (i) age &#x0003c;80 years old; (ii) transrectal prostatic biopsy; (iii) Gleason score &#x02264;8; (iv) preoperative prostate-specific antigen &#x0003c;35&#x02009;ng/ml; (v) no adjuvant radiotherapy; (vi) transrectal ultrasound; (vii) adenoma volume &#x0003c;80&#x02009;ml; (viii) not taking medication that might affect bladder function. All of the patients had Clavien Classification of Surgical Complications grades between Grade I and Grade II.<sup><xref rid="bibr12-0300060517713405" ref-type="bibr">12</xref></sup> Patients with a neurogenic bladder, history of constipation, drug allergy or any urethral, bladder neck, or prostatic surgery were excluded.</p><p>The patients were randomly assigned to the study or control group using a computer-generated randomization schedule that was prepared prior to the study commencement by a statistician not otherwise associated with the study. Patients in the study group were treated with solifenacin (5&#x02009;mg VESIcare&#x000ae;; Astellas GmbH, Munich, Germany; oral medication; once a day; for a 15-day period) beginning on the first day after surgery. Patients in the control group were treated with placebo (5&#x02009;mg vitamin C) for the 15 days. The control and study medications were identical in appearance (white round tablets).</p><p>The Ethical Committee of Shanghai Jiao Tong University Affiliated Sixth People&#x02019;s Hospital approved this study. All patients in this study provided written informed consent.</p></sec><sec id="sec4-0300060517713405"><title>Study procedures</title><p>All procedures were performed under general anaesthesia by laparoscopy using the same approach of radical prostatectomy. The operations are extraperitoneal and antegrade excision. Each patient received a drainage tube around the bladder and urethral anastomosis, and a 22 F triple lumen catheter was inserted into the bladder. The balloon was inflated within the bladder using the same volume of 15&#x02009;ml isotonic sodium chloride. The drain was removed after 2 consecutive days of &#x0003c;30&#x02009;ml output, in the absence of fever. Patients underwent the maximum uroflowmetry after catheter removal and all of the patients were examined by cystoscope for confirmation at 1 month after surgery.</p></sec><sec id="sec5-0300060517713405"><title>Study outcomes</title><p>The assessed study outcomes included the mean frequency of DO episodes during the day and night, the duration of macroscopic haematuria, the days until catheter removal, International Continence Society Short Form Male questionnaire at 2 weeks after catheter removal (ICSmale-SF),<sup><xref rid="bibr13-0300060517713405" ref-type="bibr">13</xref></sup> bladder neck stenosis episodes, and maximum urinary flow rate. A visual analogue scale (VAS) was used to measure the severity of bladder constriction. In addition to these outcomes, the side-effects after using solifenacin were also recorded.</p></sec><sec id="sec6-0300060517713405"><title>Statistical analyses</title><p>All statistical analyses were performed using the SPSS&#x000ae; statistical package, version 12.0 (SPSS Inc., Chicago, IL, USA) for Windows&#x000ae;. The baseline characteristics and perioperative data were statistically analysed using Student&#x02019;s <italic>t</italic>-test and are presented as mean&#x02009;&#x000b1;&#x02009;SD. A two-tailed test was used to compare the postoperative adverse events. A <italic>P</italic>-value &#x0003c;&#x02009;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec7-0300060517713405"><title>Results</title><p>The present study enrolled 120 patients with a mean age of 71.3 years (age range, 64&#x02013;79 years) who had histologically proven PCa and underwent LRP. The patients were randomly assigned to the study group (<italic>n</italic>&#x02009;=&#x02009;62) or the control group (<italic>n</italic>&#x02009;=&#x02009;58). The baseline characteristics and perioperative results are summarized in <xref ref-type="table" rid="table1-0300060517713405">Table 1</xref>. The groups were homogenous for age, prostate volume, Gleason score, haemoglobin decrease, operative time and preoperative prostate-specific antigen levels.
<table-wrap id="table1-0300060517713405" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Baseline demographic and clinical characteristics and perioperative data for the male patients (<italic>n</italic>&#x02009;=&#x02009;120) with histologically proven prostate cancer who participated in this study of the efficacy of solifenacin in the prevention of short-term complications following laparoscopic radical prostatectomy.</p></caption><alternatives><graphic specific-use="table1-0300060517713405" xlink:href="10.1177_0300060517713405-table1"/><table frame="hsides" rules="groups"><thead align="left" valign="top"><tr><th rowspan="1" colspan="1">Characteristic</th><th rowspan="1" colspan="1">Study group <italic>n</italic>&#x02009;=&#x02009;62</th><th rowspan="1" colspan="1">Control group <italic>n</italic>&#x02009;=&#x02009;58</th></tr></thead><tbody align="left" valign="top"><tr><td rowspan="1" colspan="1">Age, years</td><td rowspan="1" colspan="1">67.8&#x02009;&#x000b1;&#x02009;9.1</td><td rowspan="1" colspan="1">68.4&#x02009;&#x000b1;&#x02009;8.7</td></tr><tr><td rowspan="1" colspan="1">Prostate volume, ml</td><td rowspan="1" colspan="1">52.6&#x02009;&#x000b1;&#x02009;12.5</td><td rowspan="1" colspan="1">56.7&#x02009;&#x000b1;&#x02009;14.8</td></tr><tr><td rowspan="1" colspan="1">Gleason score</td><td rowspan="1" colspan="1">6.4&#x02009;&#x000b1;&#x02009;2.1</td><td rowspan="1" colspan="1">6.2&#x02009;&#x000b1;&#x02009;1.9</td></tr><tr><td rowspan="1" colspan="1">Prostate-specific antigen, ng/ml</td><td rowspan="1" colspan="1">12.5&#x02009;&#x000b1;&#x02009;6.5</td><td rowspan="1" colspan="1">14.3&#x02009;&#x000b1;&#x02009;7.3</td></tr><tr><td rowspan="1" colspan="1">Operative time, min</td><td rowspan="1" colspan="1">220.3&#x02009;&#x000b1;&#x02009;21.6</td><td rowspan="1" colspan="1">202&#x02009;&#x000b1;&#x02009;26.5</td></tr><tr><td rowspan="1" colspan="1">Haemoglobin decrease, g/dl</td><td rowspan="1" colspan="1">1.8&#x02009;&#x000b1;&#x02009;0.9</td><td rowspan="1" colspan="1">1.7&#x02009;&#x000b1;&#x02009;1.1</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-0300060517713405"><p>Data presented as mean&#x02009;&#x000b1;&#x02009;SD.</p></fn><fn id="table-fn2-0300060517713405"><p>No significant between-group differences (<italic>P</italic>&#x02009;&#x02265;&#x02009;0.05); Student&#x02019;s <italic>t</italic>-test.</p></fn></table-wrap-foot></table-wrap></p><p>All of the patients were followed-up for 1 month postoperatively and the complications were recorded. The frequency of DO during the daytime and night-time was significantly lower in patients in the study group between postoperative day (POD) 3 and POD 9 compared with the control group (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01 for all comparisons) (<xref ref-type="fig" rid="fig1-0300060517713405">Figures 1a</xref> and <xref ref-type="fig" rid="fig1-0300060517713405">1b</xref>). On the first day after surgery, DO was not significantly different between the two groups; and after POD 11, the frequency of DO gradually recovered similarly in the two groups.
<fig id="fig1-0300060517713405" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Comparison of data between the study group and the control group after surgery. The frequency of detrusor overactivity between the two groups during the daytime (a) and night-time (b) from postoperative day (POD) 1 to POD 13. The frequency of haematuresis after surgery from POD 1 until all of the patients were without haematuresis (c). Comparison of the visual analogue scale (VAS) scores between the study group and the control group from POD 1 to POD 13 (d). Data are presented as mean&#x02009;&#x000b1;&#x02009;SD. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 study group compared with the control group; Student&#x02019;s <italic>t</italic>-test.</p></caption><graphic xlink:href="10.1177_0300060517713405-fig1"/></fig></p><p>The rate of haematuria in the study group was significantly lower than in the control group between POD 7 and POD 13 (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01 for all comparisons) (<xref ref-type="fig" rid="fig1-0300060517713405">Figure 1c</xref>). All of the patients were discharged without haematuria; and the patient with the longest hospital stay was discharged on POD 18.</p><p>Two weeks after catheter removal, the total ICSmale-SF incontinence score was significantly lower in the study group compared with the control group (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01) (<xref ref-type="table" rid="table2-0300060517713405">Table 2</xref>); with significant differences being observed for the incontinence symptoms assessed by questions i2, i3 and i6 (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01 for all comparisons). There was no significant difference between the two groups in terms of voiding symptoms.
<table-wrap id="table2-0300060517713405" orientation="portrait" position="float"><label>Table 2.</label><caption><p>International Continence Society Short Form Male (ICSmale-SF) questionnaire results at 2 weeks after catheter removal for the male patients (<italic>n</italic>&#x02009;=&#x02009;120) with histologically proven prostate cancer who participated in this study of the efficacy of solifenacin in the prevention of short-term complications following laparoscopic radical prostatectomy.</p></caption><alternatives><graphic specific-use="table2-0300060517713405" xlink:href="10.1177_0300060517713405-table2"/><table frame="hsides" rules="groups"><thead align="left" valign="top"><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Study group <italic>n</italic>&#x02009;=&#x02009;62</th><th rowspan="1" colspan="1">Control group <italic>n</italic>&#x02009;=&#x02009;58</th><th rowspan="1" colspan="1">Statistical significance<sup><xref ref-type="table-fn" rid="table-fn4-0300060517713405">a</xref></sup></th></tr></thead><tbody align="left" valign="top"><tr><td colspan="4" rowspan="1">ICSmale-SF &#x02013; voiding symptoms</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Total score</td><td rowspan="1" colspan="1">6.3&#x02009;&#x000b1;&#x02009;3.1</td><td rowspan="1" colspan="1">6.8&#x02009;&#x000b1;&#x02009;2.8</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">&#x02003;v1 score</td><td rowspan="1" colspan="1">1.2&#x02009;&#x000b1;&#x02009;0.5</td><td rowspan="1" colspan="1">1.2&#x02009;&#x000b1;&#x02009;0.4</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">&#x02003;v2 score</td><td rowspan="1" colspan="1">0.8&#x02009;&#x000b1;&#x02009;0.3</td><td rowspan="1" colspan="1">0.8&#x02009;&#x000b1;&#x02009;0.2</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">&#x02003;v3 score</td><td rowspan="1" colspan="1">1.8&#x02009;&#x000b1;&#x02009;0.9</td><td rowspan="1" colspan="1">1.9&#x02009;&#x000b1;&#x02009;0.7</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">&#x02003;v4 score</td><td rowspan="1" colspan="1">0.2&#x02009;&#x000b1;&#x02009;0.1</td><td rowspan="1" colspan="1">0.4&#x02009;&#x000b1;&#x02009;0.1</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">&#x02003;v5 score</td><td rowspan="1" colspan="1">2.3&#x02009;&#x000b1;&#x02009;0.9</td><td rowspan="1" colspan="1">2.5&#x02009;&#x000b1;&#x02009;1.4</td><td rowspan="1" colspan="1">NS</td></tr><tr><td colspan="4" rowspan="1">ICSmale-SF &#x02013; incontinence symptoms</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Total score</td><td rowspan="1" colspan="1">6.8&#x02009;&#x000b1;&#x02009;1.6</td><td rowspan="1" colspan="1">12.4&#x02009;&#x000b1;&#x02009;2.3</td><td rowspan="1" colspan="1"><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01</td></tr><tr><td rowspan="1" colspan="1">&#x02003;i1 score</td><td rowspan="1" colspan="1">1.9&#x02009;&#x000b1;&#x02009;0.5</td><td rowspan="1" colspan="1">2.6&#x02009;&#x000b1;&#x02009;1.1</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">&#x02003;i2 score</td><td rowspan="1" colspan="1">1.0&#x02009;&#x000b1;&#x02009;0.4</td><td rowspan="1" colspan="1">2.5&#x02009;&#x000b1;&#x02009;1.2</td><td rowspan="1" colspan="1"><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01</td></tr><tr><td rowspan="1" colspan="1">&#x02003;i3 score</td><td rowspan="1" colspan="1">1.1&#x02009;&#x000b1;&#x02009;0.5</td><td rowspan="1" colspan="1">3.1&#x02009;&#x000b1;&#x02009;0.7</td><td rowspan="1" colspan="1"><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01</td></tr><tr><td rowspan="1" colspan="1">&#x02003;i4 score</td><td rowspan="1" colspan="1">1.8&#x02009;&#x000b1;&#x02009;0.4</td><td rowspan="1" colspan="1">1.9&#x02009;&#x000b1;&#x02009;0.6</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">&#x02003;i5 score</td><td rowspan="1" colspan="1">0.5&#x02009;&#x000b1;&#x02009;0.3</td><td rowspan="1" colspan="1">0.6&#x02009;&#x000b1;&#x02009;0.3</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">&#x02003;i6 score</td><td rowspan="1" colspan="1">0.5&#x02009;&#x000b1;&#x02009;0.2</td><td rowspan="1" colspan="1">1.7&#x02009;&#x000b1;&#x02009;0.9</td><td rowspan="1" colspan="1"><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn3-0300060517713405"><p>Data presented as mean&#x02009;&#x000b1;&#x02009;SD.</p></fn><fn id="table-fn4-0300060517713405"><label>a</label><p>Student&#x02019;s <italic>t</italic>-test.</p></fn><fn id="table-fn5-0300060517713405"><p>NS, no significant between-group difference (<italic>P</italic>&#x02009;&#x02265;&#x02009;0.05).</p></fn></table-wrap-foot></table-wrap></p><p>The mean number of days with an indwelling drainage tube and the number of days with an indwelling catheter were significantly lower in the study group compared with the control group (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01 for both comparisons) (<xref ref-type="table" rid="table3-0300060517713405">Table 3</xref>).
<table-wrap id="table3-0300060517713405" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Postoperative data recorded at 1 month post-surgery for the male patients (<italic>n</italic>&#x02009;=&#x02009;120) with histologically proven prostate cancer who participated in this study of the efficacy of solifenacin in the prevention of short-term complications following laparoscopic radical prostatectomy.</p></caption><alternatives><graphic specific-use="table3-0300060517713405" xlink:href="10.1177_0300060517713405-table3"/><table frame="hsides" rules="groups"><thead align="left" valign="top"><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Study group <italic>n</italic>&#x02009;=&#x02009;62</th><th rowspan="1" colspan="1">Control group <italic>n</italic>&#x02009;=&#x02009;58</th><th rowspan="1" colspan="1">Statistical significance<sup><xref ref-type="table-fn" rid="table-fn7-0300060517713405">a</xref></sup></th></tr></thead><tbody align="left" valign="top"><tr><td rowspan="1" colspan="1">Indwelling drainage tube, days</td><td rowspan="1" colspan="1">6.3&#x02009;&#x000b1;&#x02009;2.1</td><td rowspan="1" colspan="1">8.6&#x02009;&#x000b1;&#x02009;3.7</td><td rowspan="1" colspan="1"><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01</td></tr><tr><td rowspan="1" colspan="1">Indwelling catheter, days</td><td rowspan="1" colspan="1">10.2&#x02009;&#x000b1;&#x02009;2.6</td><td rowspan="1" colspan="1">12.7&#x02009;&#x000b1;&#x02009;3.0</td><td rowspan="1" colspan="1"><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01</td></tr><tr><td rowspan="1" colspan="1">Transient incontinence</td><td rowspan="1" colspan="1">13 (21.0)</td><td rowspan="1" colspan="1">23 (39.7)</td><td rowspan="1" colspan="1"><italic>P</italic>&#x02009;=&#x02009;0.03</td></tr><tr><td rowspan="1" colspan="1">Bladder neck stenosis</td><td rowspan="1" colspan="1">2 (3.2)</td><td rowspan="1" colspan="1">7 (12.1)</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">QMAX, ml/s</td><td rowspan="1" colspan="1">20.8&#x02009;&#x000b1;&#x02009;7.9</td><td rowspan="1" colspan="1">18.7&#x02009;&#x000b1;&#x02009;9.1</td><td rowspan="1" colspan="1">NS</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn6-0300060517713405"><p>Data presented as mean&#x02009;&#x000b1;&#x02009;SD of <italic>n</italic> of patients (%).</p></fn><fn id="table-fn7-0300060517713405"><label>a</label><p>Student&#x02019;s <italic>t</italic>-test.</p></fn><fn id="table-fn8-0300060517713405"><p>QMAX, maximum flow rate; NS, no significant between-group difference (<italic>P</italic>&#x02009;&#x02265;&#x02009;0.05).</p></fn></table-wrap-foot></table-wrap></p><p>The VAS test was conducted from the first day after surgery. The VAS score in the study group was significantly lower compared with the control group on POD 3, POD 5, POD 7 and POD 9 (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 for all comparisons) (<xref ref-type="fig" rid="fig1-0300060517713405">Figure 1d</xref>).</p><p>The 1-month postoperative data on patient bladder function are shown in <xref ref-type="table" rid="table3-0300060517713405">Table 3</xref>. A total of 13 patients (21.0%) in the study group and 23 patients (39.7%) in the control group complained of some degree of urinary incontinence (<italic>P</italic>&#x02009;=&#x02009;0.03). There was no significant difference in the rate of bladder neck stenosis or maximum flow rate between the two groups.</p><p>Of the 62 patients in the study group, 12 patients (19.4%) experienced side-effects, including dry mouth (five [8.1%]), constipation (six [9.7%]), and blurred vision (one [1.6%]). Four of 58 patients (6.9%) in the control group had symptoms of constipation.</p></sec><sec sec-type="discussion" id="sec8-0300060517713405"><title>Discussion</title><p>Prostate-specific antigen has been widely used throughout the world as a marker for the diagnosis of PCa. Although the treatment of PCa has achieved great advances in recent decades, LRP is considered the gold standard treatment for localized PCa.<sup><xref rid="bibr14-0300060517713405" ref-type="bibr">14</xref></sup> Despite increasing understanding of the pelvic anatomy and recent developments in surgical techniques, many postoperative complications occur, such as urethrovesical anastomotic urinary leakage, urinary incontinence, haematuria and bladder neck stenosis.<sup><xref rid="bibr15-0300060517713405" ref-type="bibr">15</xref></sup> It was reported that the incidence of bladder neck stenosis was between 0.48% and 32%, the incidence of urethrovesical anastomotic urinary leakage was between 0.3% to 15.4%, and the incidence of urinary incontinence was from 6% to 0.8%&#x02013;87.0%.<sup><xref rid="bibr16-0300060517713405" ref-type="bibr">16</xref>,<xref rid="bibr17-0300060517713405" ref-type="bibr">17</xref></sup> DO is a characteristic symptom of bladder dysfunction after LRP, which emerges in most patients.<sup><xref rid="bibr18-0300060517713405" ref-type="bibr">18</xref></sup> Increasing detrusor contractions can induce anastomotic bleeding and urgency, which are associated with increases in other complications.<sup><xref rid="bibr19-0300060517713405" ref-type="bibr">19</xref></sup></p><p>Acetylcholine activates muscarinic receptors on detrusor myocytes and it is the main contractile transmitter.<sup><xref rid="bibr20-0300060517713405" ref-type="bibr">20</xref></sup> Muscarinic receptors consist of five subtypes encoded by five distinct genes.<sup><xref rid="bibr21-0300060517713405" ref-type="bibr">21</xref></sup> The mRNAs for all of the muscarinic receptor subtypes have been detected in the human bladder.<sup><xref rid="bibr22-0300060517713405" ref-type="bibr">22</xref></sup> These receptors have been detected in the urothelium, interstitial cells, nerve fibres, and detrusor layers.<sup><xref rid="bibr23-0300060517713405" ref-type="bibr">23</xref></sup> Detrusor smooth muscle contains muscarinic receptors, mainly of the M2 and M3 subtypes.<sup><xref rid="bibr24-0300060517713405" ref-type="bibr">24</xref></sup> Although M2 receptors have the advantage of greater numbers, M3 receptors in the human detrusor are believed to be the most important for detrusor contraction.<sup><xref rid="bibr25-0300060517713405" ref-type="bibr">25</xref></sup> Furthermore, it was reported that M3 receptor expression was upregulated more than M2 receptor expression in patents with overactive bladder.<sup><xref rid="bibr26-0300060517713405" ref-type="bibr">26</xref></sup> Solifenacin is an antimuscarinic drug that is approved worldwide at daily doses of 5&#x02009;mg and 10&#x02009;mg for the treatment of overactive bladder; and it effectively reduces DO, bothersome storage symptoms and lower urinary tract symptoms.<sup><xref rid="bibr27-0300060517713405" ref-type="bibr">27</xref></sup> Solifenacin is an effective muscarinic receptor antagonist with selectivity for the M3 receptor in the urinary bladder.<sup><xref rid="bibr28-0300060517713405" ref-type="bibr">28</xref></sup> Solifenacin has been widely applied clinically and there are several published studies about the therapeutic effects of solifenacin after radical prostatectomy, but there are some differences in the results for urinary incontinence.<sup><xref rid="bibr9-0300060517713405" ref-type="bibr">9</xref><xref rid="bibr10-0300060517713405" ref-type="bibr"/>&#x02013;<xref rid="bibr11-0300060517713405" ref-type="bibr">11</xref></sup></p><p>Broad anatomical dissection around the prostate during surgery can disrupt afferent and efferent innervation of the trigone, neobladder neck and posterior urethra, causing outlet incompetence and partial denervation of the detrusor muscle.<sup><xref rid="bibr29-0300060517713405" ref-type="bibr">29</xref></sup> Therefore, in addition to any preoperative pathological conditions, a substantial proportion of patients are subject to various postoperative abnormalities, including DO.<sup><xref rid="bibr30-0300060517713405" ref-type="bibr">30</xref></sup> In the present study, the frequency of DO episodes was significantly lower in the study group compared with the control group during the daytime and night-time from POD 3 to POD 9. This result further confirms that solifenacin was an effective treatment for inhibiting DO. These current data showed that solifenacin was more effective between 3 days and 9 days after surgery, after which the study group showed no significant differences compared with the control group. In our opinion, this phenomenon was primarily due to the surgery, which causes anastomotic inflammation and stimulation of the bladder nervous system. Furthermore, a water-filled catheter can cause bladder irritation symptoms. As the inflammation settles and the catheter is removed, the bladder stimulus subsides, which in turn decreases bladder irritability. Solifenacin could relax the bladder muscle at the outset by preventing the effects of acetylcholine. This &#x02018;silent bladder&#x02019; could be beneficial to anastomosis healing, decreasing the time required for the vessels around bladder urethral anastomosis to close, thereby reducing the time of persistent leakage of urine or haematuria. It has been shown that the complications of bladder neck stenosis and incontinence are associated with the leakage of urine or haematuria.<sup><xref rid="bibr31-0300060517713405" ref-type="bibr">31</xref></sup> However, in this present study, the incidence of bladder neck stenosis exhibited no statistically significant difference regarding the proportion of cases between the two groups.</p><p>The ICSmale-SF was devised to evaluate the factors of voiding and incontinence symptoms.<sup><xref rid="bibr13-0300060517713405" ref-type="bibr">13</xref></sup> Unlike other questionnaires in the field, it has subscores for the domains of voiding and incontinence, including symptoms as well as separate considerations of frequency, nocturia and impact on daily life.<sup><xref rid="bibr13-0300060517713405" ref-type="bibr">13</xref></sup> In the present study, the patients using solifenacin had a significantly lower total score for the ICSmale-SF incontinence symptoms compared with the control group; in particular, for questions i2 (Does urine leak before you can get to the toilet?), i3 (Does urine leak when you cough or sneeze?) and i6 (How often have you had a slight wetting of your pants a few minutes after you had finished urinating and had dressed yourself?). Furthermore, the transient incontinence rate was significantly lower at 1 month after surgery in the study group compared with the control group. These current data demonstrate that solifenacin improved continence after LRP, possibly by reducing postoperative damage to the urethral sphincter by controlling DO.</p><p>Previous studies have shown that DO almost always occurs following lower urinary tract surgery, especially with surgical times exceeding 25 minutes.<sup><xref rid="bibr32-0300060517713405" ref-type="bibr">32</xref></sup> Furthermore, indwelling catheters have been correlated with DO, so after LRP, DO is likely to occur.<sup><xref rid="bibr32-0300060517713405" ref-type="bibr">32</xref></sup> DO not only influences the patient&#x02019;s body state, but it also induces the leakage of urine, and the extravasation of urine can promote scarring the around urethrovesical anastomosis.<sup><xref rid="bibr33-0300060517713405" ref-type="bibr">33</xref></sup> Early catheter removal has been considered an optimal method for avoiding DO.<sup><xref rid="bibr34-0300060517713405" ref-type="bibr">34</xref></sup> In this current study, the indwelling catheter remained in place until haematuria and urinary leakage has ceased. Furthermore, it was left in place for a minimum of 1 week to ensure adequate anastomotic healing. Many types of medicines can relieve DO, such as nonsteroidal anti-inflammatory drugs and opioids, but these medicines are all limited by their short duration of action or adverse effects.<sup><xref rid="bibr35-0300060517713405" ref-type="bibr">35</xref></sup> Solifenacin is believed to have a longer duration of action and fewer side-effects compared with nonsteroidal anti-inflammatory drugs and opioids.<sup><xref rid="bibr36-0300060517713405" ref-type="bibr">36</xref></sup> Dry mouth, constipation, headache, and blurred vision are generally the most frequently reported adverse events among patients treated with solifenacin.<sup><xref rid="bibr20-0300060517713405" ref-type="bibr">20</xref></sup> In the present study, the incidence of these adverse events was in agreement with those previously reported,<sup><xref rid="bibr37-0300060517713405" ref-type="bibr">37</xref></sup> further illustrating that solifenacin is a well-tolerated choice for the treatment of DO.</p><p>In this present study, all of the patients in the study group received 5&#x02009;mg/day solifenacin, but in previously published literature, both 5&#x02009;mg/day and 10&#x02009;mg/day were shown to produce very good effects.<sup><xref rid="bibr38-0300060517713405" ref-type="bibr">38</xref></sup> Future research will be required to explore the most appropriate dosage for the treatment of DO following LRP. Although this study was not a double-blind trial, which results in a low level of evidence, the 1-month follow-up results were still encouraging. Future well-designed, double-blind trials with extended follow-up and larger sample sizes will be needed to better define the role of solifenacin in the prevention of short-term complications after LRP.</p><p>In conclusion, this preliminary study showed that solifenacin was a well-tolerated and effective treatment for the prevention of complications after LRP. Compared with placebo, the main advantage of solifenacin was the decreased frequency of DO episodes during the daytime and night-time. This present study showed that this was associated with a reduction in haematuria, urinary leakage and transient incontinence, which might help patients to recover more quickly.</p></sec></body><back><sec id="sec9-0300060517713405"><title>Declaration of conflicting interests</title><p>The authors declare that there are no conflicts of interest.</p></sec><sec id="sec10-0300060517713405"><title>Funding</title><p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></sec><ref-list><title>References</title><ref id="bibr1-0300060517713405"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Naishadham</surname><given-names>D</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group>
<article-title>Cancer statistics, 2013</article-title>. <source>CA Cancer J Clin</source>
<year>2013</year>; <volume>63</volume>: <fpage>11</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">23335087</pub-id></mixed-citation></ref><ref id="bibr2-0300060517713405"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akduman</surname><given-names>B</given-names></name><name><surname>Barqawi</surname><given-names>AB</given-names></name><name><surname>Crawford</surname><given-names>ED</given-names></name></person-group>
<article-title>Minimally invasive surgery in prostate cancer: current and future perspectives</article-title>. <source>Cancer J</source>
<year>2005</year>; <volume>11</volume>: <fpage>355</fpage>&#x02013;<lpage>361</lpage>.<pub-id pub-id-type="pmid">16259865</pub-id></mixed-citation></ref><ref id="bibr3-0300060517713405"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lein</surname><given-names>M</given-names></name><name><surname>Stibane</surname><given-names>I</given-names></name><name><surname>Mansour</surname><given-names>R</given-names></name><etal>et al.</etal></person-group>
<article-title>Complications, urinary continence, and oncologic outcome of 1000 laparoscopic transperitoneal radical prostatectomies &#x02013; experience at the Charit&#x000e9; Hospital Berlin, Campus Mitte</article-title>. <source>Eur Urol</source>
<year>2006</year>; <volume>50</volume>: <fpage>1278</fpage>&#x02013;<lpage>1282</lpage>.<pub-id pub-id-type="pmid">16846677</pub-id></mixed-citation></ref><ref id="bibr4-0300060517713405"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrams</surname><given-names>P</given-names></name><name><surname>Cardozo</surname><given-names>L</given-names></name><name><surname>Fall</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<article-title>The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society</article-title>. <source>Am J Obstet Gynecol</source>
<year>2002</year>; <volume>187</volume>: <fpage>116</fpage>&#x02013;<lpage>126</lpage>.<pub-id pub-id-type="pmid">12114899</pub-id></mixed-citation></ref><ref id="bibr5-0300060517713405"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boettcher</surname><given-names>M</given-names></name><name><surname>Haselhuhn</surname><given-names>A</given-names></name><name><surname>Jakse</surname><given-names>G</given-names></name><etal>et al.</etal></person-group>
<article-title>Overactive bladder syndrome: an underestimated long-term problem after treatment of patients with localized prostate cancer?</article-title>
<source>BJU Int</source>
<year>2012</year>; <volume>109</volume>: <fpage>1824</fpage>&#x02013;<lpage>1830</lpage>.<pub-id pub-id-type="pmid">21952039</pub-id></mixed-citation></ref><ref id="bibr6-0300060517713405"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsui</surname><given-names>F</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Matsumoto</surname><given-names>F</given-names></name><etal>et al.</etal></person-group>
<article-title>Bladder function after total urogenital mobilization for persistent cloaca</article-title>. <source>J Urol</source>
<year>2009</year>; <volume>182</volume>: <fpage>2455</fpage>&#x02013;<lpage>2459</lpage>.<pub-id pub-id-type="pmid">19765763</pub-id></mixed-citation></ref><ref id="bibr7-0300060517713405"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapple</surname><given-names>CR</given-names></name></person-group>
<article-title>Muscarinic receptor antagonists in the treatment of overactive bladder</article-title>. <source>Urology</source>
<year>2000</year>; <volume>55</volume>(<issue>5A Suppl</issue>): <fpage>33</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">10767450</pub-id></mixed-citation></ref><ref id="bibr8-0300060517713405"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chancellor</surname><given-names>MB</given-names></name><name><surname>Zinner</surname><given-names>N</given-names></name><name><surname>Whitmore</surname><given-names>K</given-names></name><etal>et al.</etal></person-group>
<article-title>Efficacy of solifenacin in patients previously treated with tolterodine extended release 4&#x02009;mg: results of a 12-week, multicenter, open-label, flexible-dose study</article-title>. <source>Clin Ther</source>
<year>2008</year>; <volume>30</volume>: <fpage>1766</fpage>&#x02013;<lpage>1781</lpage>.<pub-id pub-id-type="pmid">19014833</pub-id></mixed-citation></ref><ref id="bibr9-0300060517713405"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liss</surname><given-names>MA</given-names></name><name><surname>Morales</surname><given-names>B</given-names></name><name><surname>Skarecky</surname><given-names>D</given-names></name><etal>et al.</etal></person-group>
<article-title>Phase 1 clinical trial of Vesicare&#x02122; (solifenacin) in the treatment of urinary incontinence after radical prostatectomy</article-title>. <source>J Endourol</source>
<year>2014</year>; <volume>28</volume>: <fpage>1241</fpage>&#x02013;<lpage>1245</lpage>.<pub-id pub-id-type="pmid">24924314</pub-id></mixed-citation></ref><ref id="bibr10-0300060517713405"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shim</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<article-title>The therapeutic effect of solifenacin succinate on the recovery from voiding dysfunction after radical prostatectomy in men with clinically localized prostate cancer: a prospective, randomized, controlled study</article-title>. <source>Urology</source>
<year>2015</year>; <volume>85</volume>: <fpage>1123</fpage>&#x02013;<lpage>1129</lpage>.<pub-id pub-id-type="pmid">25746580</pub-id></mixed-citation></ref><ref id="bibr11-0300060517713405"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bianco</surname><given-names>FJ</given-names></name><name><surname>Albala</surname><given-names>DM</given-names></name><name><surname>Belkoff</surname><given-names>LH</given-names></name><etal>et al.</etal></person-group>
<article-title>A randomized, double-blind, solifenacin succinate versus placebo control, phase 4, multicenter study evaluating urinary continence after robotic assisted radical prostatectomy</article-title>. <source>J Urol</source>
<year>2015</year>; <volume>193</volume>: <fpage>1305</fpage>&#x02013;<lpage>1310</lpage>.<pub-id pub-id-type="pmid">25281778</pub-id></mixed-citation></ref><ref id="bibr12-0300060517713405"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dindo</surname><given-names>D</given-names></name><name><surname>Demartines</surname><given-names>N</given-names></name><name><surname>Clavien</surname><given-names>PA</given-names></name></person-group>
<article-title>Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey</article-title>. <source>Ann Surg</source>
<year>2004</year>; <volume>240</volume>: <fpage>205</fpage>&#x02013;<lpage>213</lpage>.<pub-id pub-id-type="pmid">15273542</pub-id></mixed-citation></ref><ref id="bibr13-0300060517713405"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donovan</surname><given-names>JL</given-names></name><name><surname>Peters</surname><given-names>TJ</given-names></name><name><surname>Abrams</surname><given-names>P</given-names></name><etal>et al.</etal></person-group>
<article-title>Scoring the short form ICSmaleSF questionnaire. International continence society</article-title>. <source>J Urol</source>
<year>2000</year>; <volume>164</volume>: <fpage>1948</fpage>&#x02013;<lpage>1955</lpage>.<pub-id pub-id-type="pmid">11061889</pub-id></mixed-citation></ref><ref id="bibr14-0300060517713405"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heidenreich</surname><given-names>A</given-names></name><name><surname>Bellmunt</surname><given-names>J</given-names></name><name><surname>Bolla</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<article-title>EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease</article-title>. <source>Eur Urol</source>
<year>2011</year>; <volume>59</volume>: <fpage>61</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">21056534</pub-id></mixed-citation></ref><ref id="bibr15-0300060517713405"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walz</surname><given-names>J</given-names></name><name><surname>Burnett</surname><given-names>AL</given-names></name><name><surname>Costello</surname><given-names>AJ</given-names></name><etal>et al.</etal></person-group>
<article-title>A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy</article-title>. <source>Eur Urol</source>
<year>2010</year>; <volume>57</volume>: <fpage>179</fpage>&#x02013;<lpage>192</lpage>.<pub-id pub-id-type="pmid">19931974</pub-id></mixed-citation></ref><ref id="bibr16-0300060517713405"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geary</surname><given-names>ES</given-names></name><name><surname>Dendinger</surname><given-names>TE</given-names></name><name><surname>Freiha</surname><given-names>FS</given-names></name><etal>et al.</etal></person-group>
<article-title>Incontinence and vesical neck strictures following radical retropubic prostatectomy</article-title>. <source>Urology</source>
<year>1995</year>; <volume>45</volume>: <fpage>1000</fpage>&#x02013;<lpage>1006</lpage>.<pub-id pub-id-type="pmid">7771001</pub-id></mixed-citation></ref><ref id="bibr17-0300060517713405"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyritzis</surname><given-names>SI</given-names></name><name><surname>Katafigiotis</surname><given-names>I</given-names></name><name><surname>Constantinides</surname><given-names>CA</given-names></name></person-group>
<article-title>All you need to know about urethrovesical anastomotic urinary leakage following radical prostatectomy</article-title>. <source>J Urol</source>
<year>2012</year>; <volume>188</volume>: <fpage>369</fpage>&#x02013;<lpage>376</lpage>.<pub-id pub-id-type="pmid">22698622</pub-id></mixed-citation></ref><ref id="bibr18-0300060517713405"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giannantoni</surname><given-names>A</given-names></name><name><surname>Mearini</surname><given-names>E</given-names></name><name><surname>Zucchi</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<article-title>Bladder and urethral sphincter function after radical retropubic prostatectomy: a prospective long-term study</article-title>. <source>Eur Urol</source>
<year>2008</year>; <volume>54</volume>: <fpage>657</fpage>&#x02013;<lpage>664</lpage>.<pub-id pub-id-type="pmid">18006215</pub-id></mixed-citation></ref><ref id="bibr19-0300060517713405"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porena</surname><given-names>M</given-names></name><name><surname>Mearini</surname><given-names>E</given-names></name><name><surname>Mearini</surname><given-names>L</given-names></name><etal>et al.</etal></person-group>
<article-title>Voiding dysfunction after radical retropubic prostatectomy: More than external urethral sphincter deficiency</article-title>. <source>Eur Urol</source>
<year>2007</year>; <volume>52</volume>: <fpage>38</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">17403565</pub-id></mixed-citation></ref><ref id="bibr20-0300060517713405"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrams</surname><given-names>P</given-names></name><name><surname>Andersson</surname><given-names>KE</given-names></name></person-group>
<article-title>Muscarinic receptor antagonists for overactive bladder</article-title>. <source>BJU Int</source>
<year>2007</year>; <volume>100</volume>: <fpage>987</fpage>&#x02013;<lpage>1006</lpage>.<pub-id pub-id-type="pmid">17922784</pub-id></mixed-citation></ref><ref id="bibr21-0300060517713405"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caulfield</surname><given-names>MP</given-names></name><name><surname>Birdsall</surname><given-names>NJ</given-names></name></person-group>
<article-title>International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors</article-title>. <source>Pharmacol Rev</source>
<year>1998</year>; <volume>50</volume>: <fpage>279</fpage>&#x02013;<lpage>290</lpage>.<pub-id pub-id-type="pmid">9647869</pub-id></mixed-citation></ref><ref id="bibr22-0300060517713405"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sigala</surname><given-names>S</given-names></name><name><surname>Mirabella</surname><given-names>G</given-names></name><name><surname>Peroni</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<article-title>Differential gene expression of cholinergic muscarinic receptor subtypes in male and female normal human urinary bladder</article-title>. <source>Urology</source>
<year>2002</year>; <volume>60</volume>: <fpage>719</fpage>&#x02013;<lpage>725</lpage>.<pub-id pub-id-type="pmid">12385950</pub-id></mixed-citation></ref><ref id="bibr23-0300060517713405"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukerji</surname><given-names>G</given-names></name><name><surname>Yiangou</surname><given-names>Y</given-names></name><name><surname>Grogono</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>
<article-title>Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations</article-title>. <source>J Urol</source>
<year>2006</year>; <volume>176</volume>: <fpage>367</fpage>&#x02013;<lpage>373</lpage>.<pub-id pub-id-type="pmid">16753445</pub-id></mixed-citation></ref><ref id="bibr24-0300060517713405"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eglen</surname><given-names>RM</given-names></name></person-group>
<article-title>Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function</article-title>. <source>Auton Autacoid Pharmacol</source>
<year>2006</year>; <volume>26</volume>: <fpage>219</fpage>&#x02013;<lpage>233</lpage>.<pub-id pub-id-type="pmid">16879488</pub-id></mixed-citation></ref><ref id="bibr25-0300060517713405"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>KE</given-names></name><name><surname>Wein</surname><given-names>AJ</given-names></name></person-group>
<article-title>Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence</article-title>. <source>Pharmacol Rev</source>
<year>2004</year>; <volume>56</volume>: <fpage>581</fpage>&#x02013;<lpage>631</lpage>.<pub-id pub-id-type="pmid">15602011</pub-id></mixed-citation></ref><ref id="bibr26-0300060517713405"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapple</surname><given-names>CR</given-names></name><name><surname>Yamanishi</surname><given-names>T</given-names></name><name><surname>Chess-Williams</surname><given-names>R</given-names></name></person-group>
<article-title>Muscarinic receptor subtypes and management of the overactive bladder</article-title>. <source>Urology</source>
<year>2002</year>; <volume>60</volume>(<issue>5 Suppl 1</issue>): <fpage>82</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">12493364</pub-id></mixed-citation></ref><ref id="bibr27-0300060517713405"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Kerrebroeck</surname><given-names>P</given-names></name><name><surname>Chapple</surname><given-names>C</given-names></name><name><surname>Drogendijk</surname><given-names>T</given-names></name><etal>et al.</etal></person-group>
<article-title>Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial</article-title>. <source>Eur Urol</source>
<year>2013</year>; <volume>64</volume>: <fpage>1003</fpage>&#x02013;<lpage>1012</lpage>.<pub-id pub-id-type="pmid">23932438</pub-id></mixed-citation></ref><ref id="bibr28-0300060517713405"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ronchi</surname><given-names>P</given-names></name><name><surname>Gravina</surname><given-names>GL</given-names></name><name><surname>Galatioto</surname><given-names>GP</given-names></name><etal>et al.</etal></person-group>
<article-title>Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity</article-title>. <source>Neurourol Urodyn</source>
<year>2009</year>; <volume>28</volume>: <fpage>52</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="pmid">18671288</pub-id></mixed-citation></ref><ref id="bibr29-0300060517713405"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giannantoni</surname><given-names>A</given-names></name><name><surname>Mearini</surname><given-names>E</given-names></name><name><surname>Di Stasi</surname><given-names>SM</given-names></name><etal>et al.</etal></person-group>
<article-title>Assessment of bladder and urethral sphincter function before and after radical retropubic prostatectomy</article-title>. <source>J Urol</source>
<year>2004</year>; <volume>171</volume>: <fpage>1563</fpage>&#x02013;<lpage>1566</lpage>.<pub-id pub-id-type="pmid">15017221</pub-id></mixed-citation></ref><ref id="bibr30-0300060517713405"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>R</given-names></name><name><surname>Mayo</surname><given-names>ME</given-names></name></person-group>
<article-title>Incontinence after radical prostatectomy: detrusor or sphincter causes</article-title>. <source>J Urol</source>
<year>1995</year>; <volume>154</volume>: <fpage>16</fpage>&#x02013;<lpage>18</lpage>.<pub-id pub-id-type="pmid">7776413</pub-id></mixed-citation></ref><ref id="bibr31-0300060517713405"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yurkanin</surname><given-names>JP</given-names></name><name><surname>Dalkin</surname><given-names>BL</given-names></name><name><surname>Cui</surname><given-names>H</given-names></name></person-group>
<article-title>Evaluation of cold knife urethrotomy for the treatment of anastomotic stricture after radical retropubic prostatectomy</article-title>. <source>J Urol</source>
<year>2001</year>; <volume>165</volume>: <fpage>1545</fpage>&#x02013;<lpage>1548</lpage>.<pub-id pub-id-type="pmid">11342914</pub-id></mixed-citation></ref><ref id="bibr32-0300060517713405"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yates</surname><given-names>V</given-names></name><name><surname>Tanner</surname><given-names>J</given-names></name><name><surname>Crossley</surname><given-names>A</given-names></name></person-group>
<article-title>Bladder spasm following transurethral surgery</article-title>. <source>Br J Perioper Nurs</source>
<year>2004</year>; <volume>14</volume>: <fpage>259</fpage>&#x02013;<lpage>260</lpage>.<pub-id pub-id-type="pmid">15704735</pub-id></mixed-citation></ref><ref id="bibr33-0300060517713405"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montgomery</surname><given-names>JS</given-names></name><name><surname>Gayed</surname><given-names>BA</given-names></name><name><surname>Daignault</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<article-title>Early urinary retention after catheter removal following radical prostatectomy predicts for future symptomatic urethral stricture formation</article-title>. <source>Urology</source>
<year>2007</year>; <volume>70</volume>: <fpage>324</fpage>&#x02013;<lpage>327</lpage>.<pub-id pub-id-type="pmid">17826498</pub-id></mixed-citation></ref><ref id="bibr34-0300060517713405"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>MO</given-names></name><name><surname>Nayee</surname><given-names>AH</given-names></name><name><surname>Sloan</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>
<article-title>Early catheter removal after radical retropubic prostatectomy: long-term followup</article-title>. <source>J Urol</source>
<year>2003</year>; <volume>169</volume>: <fpage>2170</fpage>&#x02013;<lpage>2172</lpage>.<pub-id pub-id-type="pmid">12771741</pub-id></mixed-citation></ref><ref id="bibr35-0300060517713405"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>I</given-names></name><name><surname>Nagase</surname><given-names>K</given-names></name><name><surname>Tanase</surname><given-names>K</given-names></name><etal>et al.</etal></person-group>
<article-title>Improvement in neurogenic detrusor overactivity by peripheral C fiber&#x02019;s suppression with cyclooxygenase inhibitors</article-title>. <source>J Urol</source>
<year>2010</year>; <volume>183</volume>: <fpage>786</fpage>&#x02013;<lpage>792</lpage>.<pub-id pub-id-type="pmid">20022033</pub-id></mixed-citation></ref><ref id="bibr36-0300060517713405"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brostr&#x000f8;m</surname><given-names>S</given-names></name><name><surname>Hallas</surname><given-names>J</given-names></name></person-group>
<article-title>Persistence of antimuscarinic drug use</article-title>. <source>Eur J Clin Pharmacol</source>
<year>2009</year>; <volume>65</volume>: <fpage>309</fpage>&#x02013;<lpage>314</lpage>.<pub-id pub-id-type="pmid">19107469</pub-id></mixed-citation></ref><ref id="bibr37-0300060517713405"><label>37</label><mixed-citation publication-type="other"><comment>VESIcare&#x000ae; (solifenacin succinate). Full Prescribing Information. Yamanouchi Pharma America Inc. and GlaxoSmithKline, Norman, OK, USA; 2004. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21518lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21518lbl.pdf</ext-link> (accessed 18 May 2017)</comment>.</mixed-citation></ref><ref id="bibr38-0300060517713405"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapple</surname><given-names>CR</given-names></name><name><surname>Khullar</surname><given-names>V</given-names></name><name><surname>Gabriel</surname><given-names>Z</given-names></name><etal>et al.</etal></person-group>
<article-title>The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis</article-title>. <source>Eur Urol</source>
<year>2008</year>; <volume>54</volume>: <fpage>543</fpage>&#x02013;<lpage>562</lpage>.<pub-id pub-id-type="pmid">18599186</pub-id></mixed-citation></ref></ref-list></back></article>